The meeting, which was also attended by Ivanka Trump and Reed Cordish, assistant to the president, examined the relationship between government, universities, philanthropy and industry that make American biomedical discovery “the envy of the world,” NIH Director Francis Collins said in a statement.
Coupled with the lack of an updated defense research and development (R&D) strategy to help focus U.S. investments and rally the U.S. R&D community, inefficiencies in the U.S. defense technology pipeline (where decades can elapse before an innovation finds its way into the hands of the warfighter), are crippling the technology advantage of the U.S. military. The United States must act purposefully and with urgency to reclaim U.S. leadership in defense innovation and restore America’s technological advantage.
Our machine is the envy of the world. And yet, while other nations, such as China, are working furiously to develop their own Miracle Machines, we’ve been neglecting ours. Though historically a bipartisan priority, science and technology funding has steadily eroded over the past decade. One example among many: Adjusted for inflation, the budget for the National Institutes of Health, the federal medical research agency, has fallen since 2003 by nearly 25 percent .
Space is the subject of much wonder and fantasy, as well as research and debate. Currently, that debate tends to center around whether or not funding for space exploration and research should be cut in favor of other pressing needs, such as education and the environment, and it should not be.
Volunteers supported by SPIE, the international society for optics and photonics, joined other scientists, researchers, engineers, and industry professionals in visiting U.S. Congressional offices in Washington, D.C., yesterday to urge support for measures to strengthen America's ability to compete in the world photonics industry.
Flat-panel displays, lithium ion batteries, digital mobile handsets, notebook computers and photovoltaic cells and panels are just a few of the products created with technologies invented in the United States, but largely commercialized elsewhere. How can that be when U.S. companies spend more than $300 billion annually on R&D?
The initial federal research investment is small. Eighty percent of the companies in the report cited less than $5 million as the amount of federal funding received for their foundational work. For 40 percent of companies, this amount was less than $1 million. The 102 companies highlighted are predominantly small businesses, like most companies in the United States. Sixty-five percent of companies have fewer than 100 employees. Yet, the companies collectively employ 8,900 people.
While the United States is still at the top in total investment in research and development -- spending $500 billion in 2015 -- a new Boston Consulting Group (BCG) study released Monday has made a startling finding: A couple of years ago, China quietly surpassed the U.S. in spending on the later stage of R&D that turns discoveries into commercial products.
NCSES reported that within the R&D total, research obligations -- a category of transactions including orders placed, contracts awarded and services received -- increased by 1 percent to $63.6 billion. At the same time, development funding fell by 4 percent to $64.9 billion and R&D plant rose a substantial 27 percent to $2.8 billion.
Electrical stimulation of the spinal cord and intense physical therapy have been used by Mayo Clinic researchers to help Jared Chinnock intentionally move his paralyzed legs, stand, and make steplike motions for the first time in three years. The chronic traumatic paraplegia case marks the first time a patient has intentionally controlled previously paralyzed functions within the first two weeks of stimulation.